Summary of the values of maximal active force, pCa50 and nH before and after PKA treatment in PLV after reconstitution with cTn or PCRF or treatment with PP1
| Maximal force (mN/mm2) | pCa50 | nH | |
| Fig. 2 C | |||
| Control PLV | 55.99 ± 5.92 | 5.55 ± 0.01 | 4.23 ± 0.25 |
| cTn | 52.52 ± 5.48 | 5.62 ± 0.01a | 4.15 ± 0.35 |
| cTn+PKA | 51.17 ± 5.42 | 5.46 ± 0.01ab | 4.56 ± 0.30 |
| Fig. 2 D | |||
| Control PLV | 53.85 ± 6.03 | 5.55 ± 0.02 | 4.16 ± 0.16 |
| PCRF | 51.42 ± 5.35 | 5.64 ± 0.03a | 3.69 ± 0.16 |
| PCRF + PKA | 49.86 ± 5.32 | 5.46 ± 0.01ab | 3.92 ± 0.18 |
| Fig. 3 B | |||
| Control PLV | 59.32 ± 4.51 | 5.55 ± 0.01 | 4.12 ± 0.16 |
| PP1 | 56.47 ± 5.70 | 5.64 ± 0.02a | 4.24 ± 0.35 |
| PP1 + PKA | 54.10 ± 5.66 | 5.46 ± 0.01ab | 4.05 ± 0.20 |
| Maximal force (mN/mm2) | pCa50 | nH | |
| Control PLV | 55.99 ± 5.92 | 5.55 ± 0.01 | 4.23 ± 0.25 |
| cTn | 52.52 ± 5.48 | 5.62 ± 0.01 | 4.15 ± 0.35 |
| cTn+PKA | 51.17 ± 5.42 | 5.46 ± 0.01 | 4.56 ± 0.30 |
| Control PLV | 53.85 ± 6.03 | 5.55 ± 0.02 | 4.16 ± 0.16 |
| PCRF | 51.42 ± 5.35 | 5.64 ± 0.03 | 3.69 ± 0.16 |
| PCRF + PKA | 49.86 ± 5.32 | 5.46 ± 0.01 | 3.92 ± 0.18 |
| Control PLV | 59.32 ± 4.51 | 5.55 ± 0.01 | 4.12 ± 0.16 |
| PP1 | 56.47 ± 5.70 | 5.64 ± 0.02 | 4.24 ± 0.35 |
| PP1 + PKA | 54.10 ± 5.66 | 5.46 ± 0.01 | 4.05 ± 0.20 |
Maximal force was obtained by activating muscle at pCa 4.5 before plotting of the force-pCa curve at each condition.
P < 0.05 compared with the corresponding values for control PLV (before thin filament reconstitution or PP1 treatment).
P < 0.05 compared with the corresponding values for thin filament reconstitution or PP1 treatment (before PKA treatment).
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.